Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus XIFYRM.
MUPIROCIN vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
500 mg orally twice daily with food.
None Documented
None Documented
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category A/B
Category C
Antibiotic
Antibiotic